DOCSLIB.ORG

National Master List of Drugs and Lab Reagents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

* Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1Aa Digtalis glycoside 02-01-00001 digoxin tab 62.5 mcg 800000 02-01-00002 digitoxin tab 100 mcg 800000 02-01-00003 digoxin tab 125 mcg 800000 02-01-00004 digoxin tab 250 mcg 15000000 02-01-00005 digoxin PG elixir 50mcg /ml 800000 02-01-00006 digoxin inj 250 mcg/ml, (2ml amp) 800000 1Ab PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone inj 5mg/ml (20ml amp) 800000 1B DIURETICS 02-01-00008 amiloride Hcl 5mg + hydrochlorthiazide 50mg tab 50000000 02-01-00009 bumetanide tab 1 mg 800000 02-01-00010 chlorthalidone tab 50mg 2867000 02-01-00011 ethacrynic acid as sod.salt inj powder for reconstitution 50mg vial 800000 02-01-00012 frusemide inj 20mg/2ml amp 6625000 02-01-00013 frusemide I.V. infusion inj 10mg/ml, (25ml amp) 800000 02-01-00014 frusemide tab 40mg 20000000 02-01-00015 frusemide scored tab 500mg 800000 02-01-00016 frusemide oral solution pead liquid 1mg/1ml 800000 02-01-00017 frusemide oral solution 4mg/ml 800000 02-01-00018 frusemide oral solution 8mg/ml 800000 02-01-00019 hydrochlorothiazide tab 25mg 800000 02-01-00020 hydrochlorothiazide tab 50mg 950000 02-01-00021 indapamide tab 2.5mg 800000 02-01-00022 Indapamide s/r coated tab 1.5mg 800000 02-01-00023 spironolactone tab 25mg 7902000 02-01-00024 spironolactone tab 100mg 11451000 02-01-00025 Xipamide tab 20mg 800000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 acebutolol tab 100mg 800000 02-01-00027 acebutolol tab 200mg 800000 02-01-00028 atenolol tab 100mg 120000000 02-01-00029 atenolol tab or (scored tab) 50mg 20000000 02-01-00030 atenolol tab 25mg 1483000 02-01-00031 Bisoprolol fumarate scored tab 5mg 800000 02-01-00032 Bisoprolol fumarate scored tab 10mg 800000 02-01-00033 Carvedilol 6.25mg tab 800000 02-01-00034 Carvedilol 12.5mg tab 800000 02-01-00035 Carvedilol 25mg tab 800000 02-01-00036 Esmolol Hcl IV infusion 10mg/ml (10ml vial) 800000 02-01-00037 labetalol inj 5mg/ml (20ml amp) 800000 02-01-00038 labetalol tab 200mg 800000 02-01-00039 labetalol tab 400mg 800000 02-01-00040 metoprolol tab 50mg 800000 02-01-00041 metoprolol tab (s/r) 200mg 1599000 02-01-00042 metoprolol tartrate I.V. inj 1mg/1ml (5ml amp) 800000 02-01-00043 metoprolol tartrate 100mg (CR)(ZOK) tab 800000 02-01-00044 metoprolol tartrate 50mg (CR)(ZOK) tab 800000 02-01-00045 nadolol tab 80mg 800000 02-01-00046 oxprenolol Hcl tab 40mg 4000000 02-01-00047 pindolol tab 5mg 800000 02-01-00048 propranolol Hcl slow IV inj 1mg/ml (1ml amp) 800000 02-01-00049 propranolol Hcl tab 10mg 20000000 1 of 119 MOH CODE ITEM NAME 02-01-00050 propranolol Hcl tab (or scored tab) 40mg 50000000 02-01-00051 propranolol Hcl cap (s/r) 80mg 800000 02-01-00052 sotalol tab 40mg 800000 02-01-00053 sotalol tab 80mg 800000 1D ANTI-ARRHYTHMIC DRUGS 02-01-00054 amiodarone Hcl inj 50mg/ml (3ml amp) 800000 02-01-00055 Amiodarone Hcl tab 200mg 9208000 02-01-00056 bretylium tosylate inj 50mg/ml,( 10ml amp) 800000 02-01-00057 disopyramide caps 100mg 2829000 02-01-00058 disopyramide tab (s/r) durules 150mg 800000 02-01-00059 disopyramide tab retard (s/r) 250mg 800000 02-01-00060 disopyramide inj 10mg/ml, (5ml amp) 800000 02-01-00061 lignocaine Hcl slow I.V. infusion inj 20mg/ml, (50ml vial) plain 800000 02-01-00062 lignocaine Hcl 5%+dextrose 7.5% inj Hyperbaric sol.spinal anesthesia 800000 02-01-00063 lignocaine Hcl 1.5%+dextrose 7.5% inj Hyperbaric sol.spinal anesthesia 800000 02-01-00064 mexiletine Hcl caps 50mg 800000 02-01-00065 mexiletine Hcl caps 200mg 1550000 02-01-00066 mexiletine Hcl IV,IV infusion inj 25mg/ml, (10ml amp) 800000 02-01-00067 phenytoin sod.inj 50mg/ml, (5ml amp) 800000 02-01-00068 practolol inj 2mg/ml, (5ml amp) 800000 02-01-00069 procainamide Hcl slow I.V.I.V infusion inj 100mg/ml, (10ml vial) 800000 02-01-00070 procainamide Hcl tab 500mg 800000 02-01-00071 procainamide Hcl tab (s/r) 750mg 800000 02-01-00072 propafenon Hcl tab 150mg 800000 02-01-00073 quinidine Bisulfate tab (s/r) 250mg =quinidine sulphate 200mg (Durules) 800000 02-01-00074 quinidine Sulphate tab 200mg 800000 02-01-00075 verapamil Hcl inj 2.5mg/ml, (2ml amp) 800000 02-01-00076 verapamil Hcl tab 40mg 5588000 02-01-00077 verapamil Hcl tab 80mg 835000 02-01-00078 verapamil Hcl tab (s/r) 120mg or cap, 800000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00079 alfuzosin Hcl tab 2.5mg 952000 02-01-00080 alfuzosin Hcl (S/R) tab 5mg 964000 02-01-00081 captopril tab 25mg 120000000 02-01-00082 captopril tab 50mg 60000000 02-01-00083 captopril tab 12.5mg 800000 02-01-00084 Candesartan cilexetil scored tab 8mg 800000 02-01-00085 diazoxide tab 50mg 800000 02-01-00086 doxazosin scored tab 2mg 2506000 02-01-00087 doxazosin mesylate tab 1mg 800000 02-01-00089 doxazosin mesylate tab 4mg 800000 02-01-00090 enalapril maleate scored tab 5mg 1925000 02-01-00091 enalapril maleate scored tab 10mg 2250000 02-01-00092 enalapril maleate scored tab 20mg 1774000 02-01-00093 hydralazine Hcl I.V. infusion inj 20mg per amp 800000 02-01-00094 hydralazine Hcl tab 25mg 837000 02-01-00095 hydralazine Hcl tab 50mg 800000 02-01-00096 Lisinopril tab 5mg 3664000 02-01-00097 Lisinopril tab 10mg 4145000 02-01-00098 Lisinopril tab 20mg 3712000 02-01-00099 Losartan potassium tab 50mg 800000 02-01-00100 Irbesartan 150mg tab 800000 02-01-00101 Irbesartan 300mg tab 800000 02-01-00102 methyldopa inj 50mg/ml, (5ml amp) 800000 02-01-00103 methyldopa tab 250mg 50000000 02-01-00104 minoxidil tab 5mg 800000 02-01-00105 minoxidil tab 10mg 800000 02-01-00106 Perindopril Tert-butylamine erbumine 2mg tab 800000 2 of 119 MOH CODE ITEM NAME 02-01-00107 Perindopril Tert-butylamine erbumine 4mg tab 800000 02-01-00108 phenoxybenzamine Hcl caps 10mg 800000 02-01-00109 phenoxybenzamine Hcl inj 50mg/ml, (2ml amp) 800000 02-01-00110 phentolamine mesylate inj 10mg/ml, (1ml amp) 800000 02-01-00111 prazosin Hcl tab 0.5mg 800000 02-01-00112 prazosin Hcl tab or scored tab 1mg 4172000 02-01-00113 prazosin Hcl tab 2mg 800000 02-01-00114 prazosin Hcl tab 5mg 800000 02-01-00115 Quinapril Hcl tab 5mg 800000 02-01-00116 Quinapril Hcl tab 10mg 800000 02-01-00117 Quinapril Hcl tab 20mg 800000 02-01-00118 Ramipril scored tab or cap: 2.5mg 800000 02-01-00119 Ramipril scored tab or cap: 5mg 800000 02-01-00120 Ramipril scored tab or cap: 10mg 800000 02-01-00121 Ramipril cap: 1.25mg 800000 02-01-00122 reserpine tab 100mcg 800000 02-01-00123 Sodium nitroprusside I.V. infusion 50mg amp or vial with solvent or Sod.nitroprusside infusion 800000 30mg/ amp with solvent 02-01-00124 tolazoline Hcl inj i.v 800000 02-01-00125 Valsartan cap 160mg 8000000 02-01-00126 Valsartan cap 40mg 8000000 02-01-00127 Valsartan cap 80mg 8000000 02-01-00128 Valsartan 80mg+hydrochlorthiozide 12.5mg cap or tab 8000000 02-01-00129 Valsartan 160mg+hydrochlorthiozide 12.5mg cap or tab 8000000 02-01-00130 Telmisartan 40mg tab 8000000 02-01-00131 Telmisartan 80mg tab 8000000 1F VASODILATORS 02-01-00132 Amlodipine (as besylate) tab 2.5mg 800000 02-01-00133 Amlodipine (as besylate) scored tab 5mg 1125000 02-01-00134 Amlodipine (as besylate) scored tab 10mg 9071000 02-01-00135 cinnarizine tab 25mg 15000000 02-01-00136 cinnarizine cap or tab 75mg 4529000 02-01-00137 diltiazem Hcl cap or tab 60mg normal release 7980000 02-01-00138 diltiazem Hcl cap or tab (s/r) 90mg 3365000 02-01-00139 diltiazem Hcl cap or tab (s/r) 120mg 3356000 02-01-00140 diltiazem Hcl cap or tab (s/r) 180mg 800000 02-01-00141 diltiazem Hcl cap or tab (s/r) 240mg or 200mg 800000 02-01-00142 diltiazem Hcl cap or tab (s/r) 300mg 800000 02-01-00143 diltiazem Hcl IV inj or infusion 25mg/vial 800000 02-01-00144 Felodipine 5mg tab 800000 02-01-00145 glyceryl trinitrate tab 0. 5mg 40000000 02-01-00146 glyceryl trinitrate inj 5mg/10ml amp. 800000 02-01-00147 glyceryl trinitrate plaster 5mg 800000 02-01-00148 glyceryl trinitrate plaster 10mg 800000 02-01-00149 glyceryl trinitrate plaster 15mg 800000 02-01-00150 glyceryl trinitrate plaster 25mg 800000 02-01-00151 glyceryl trinitrate spray 800000 02-01-00152 glyceryl trinitrate tab (c/r) 2.6mg 800000 02-01-00153 glyceryl trinitrate tab (c/r) 6.4mg 800000 02-01-00154 isosorbide dinitrate tab (s/l) 5mg 10238000 02-01-00155 isosorbide dinitrate tab 10mg 130000000 02-01-00156 isosorbide dinitrate tab (s/r) 20mg 942000 02-01-00157 isosorbide dinitrate tab (s/r) 40mg 800000 02-01-00158 Isosorbide dinitrate 1.25mg/ 0.09ml spray 800000 02-01-00159 isosorbide mononitrate tab 10mg 800000 02-01-00160 isosorbide mononitrate tab or cap 20mg 800000 02-01-00161 Isosorbide mononitrate 40 mg tab 800000 02-01-00162 Isosorbide mononitrate 60 mg tab 800000 3 of 119 MOH CODE ITEM NAME 02-01-00163 isosorbide mononitrate tab(s/r)25mg or cap 800000 02-01-00164 isosorbide mononitrate tab(s/r)50mg or cap 800000 02-01-00165 isosorbide 5 mononitrate 60mg tab(controlled release formulation) 800000 02-01-00166 Nicardipine Hcl IV inj 25mg (solution)/ amp 800000 02-01-00167 Nicardipine Hcl 50mg s/r cap or pellets 800000 02-01-00168 nifedipine caps 5mg 10774000 02-01-00169 nifedipine caps 10mg 3423000 02-01-00170 nifedipine (s/r) caps or tab 10mg 22898000 02-01-00171 nifedipine caps or tab (s/r) 20mg 50000000 02-01-00172 nifedipine caps or tab (s/r) 30mg (24hr) 10745000 02-01-00173 nifedipine caps (s/r) 60mg (24hr) 10000000 02-01-00174 nimodipine tab 30mg 800000 02-01-00175 nimodipine i.v infusion 200mcg/ml (50ml vial) 800000 02-01-00176 oxpentifylline tab 400mg (pentoxifylline) 3747000 02-01-00177 oxpentifylline tab 600mg (pentoxifylline)
Recommended publications
  • DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

    DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

    DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Reinhardt, H. Christian, Pia Hasskamp, Ingolf Schmedding, Sandra Morandell, Marcel A.T.M. van Vugt, XiaoZhe Wang, Rune Linding, et al. “DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization.” Molecular Cell 40, no. 1 (October 2010): 34–49.© 2010 Elsevier Inc. As Published http://dx.doi.org/10.1016/j.molcel.2010.09.018 Publisher Elsevier B.V. Version Final published version Citable link http://hdl.handle.net/1721.1/85107 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Molecular Cell Article DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization H. Christian Reinhardt,1,6,7,8 Pia Hasskamp,1,10,11 Ingolf Schmedding,1,10,11 Sandra Morandell,1 Marcel A.T.M. van Vugt,5 XiaoZhe Wang,9 Rune Linding,4 Shao-En Ong,2 David Weaver,9 Steven A. Carr,2 and Michael B. Yaffe1,2,3,* 1David H. Koch Institute for Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02132, USA 2Broad Institute of MIT and Harvard, Cambridge, MA 02132, USA 3Center for Cell Decision Processes,
  • Adrenal Disorders

    Adrenal Disorders

    Adrenal Disorders Dual-release Hydrocortisone in Addison’s Disease— A Review of the Literature Roberta Giordano, MD,1 Federica Guaraldi, MD,2 Rita Berardelli, MD,2 Ioannis Karamouzis, MD,2 Valentina D’Angelo, MD,2 Clizia Zichi, MD,2 Silvia Grottoli, MD,2 Ezio Ghigo, PhD2 and Emanuela Arvat, PhD3 1. Department of Clinical and Biological Sciences; 2. Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences; 3. Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy Abstract In patients with adrenal insufficiency, glucocorticoids (GCs) are insufficiently secreted and GC replacement is essential for health and, indeed, life. Despite GC-replacement therapy, patients with adrenal insufficiency have a greater cardiovascular risk than the general population, and suffer from impaired health-related quality of life. Although the aim of the replacement GC therapy is to reproduce as much as possible the physiologic pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm. Therefore, there is an unmet clinical need for the development of novel pharmaceutical preparations of hydrocortisone, in order to guarantee a more physiologic serum cortisol concentration time-profile, and to improve the long-term outcome in patients under GC substitution therapy. Keywords Addison’s disease, glucocorticoids, hydrocortisone, Plenadren®, limits, advantages Disclosure: The authors have no conflicts of interest to declare. Received: June 28, 2013 Accepted: August 9, 2013 Citation: US Endocrinology 2013;9(2):177–80 DOI: 10.17925/USE.2013.09.02.177 Correspondence: Roberta Giordano, MD, Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, Azienda Ospedaliera Città della Salute e della Scienza di Torino, C so Dogliotti 14, 10126 Turin, Italy.
  • Dansylated Estramustine, a Fluorescent Probe for Studies Of

    Dansylated Estramustine, a Fluorescent Probe for Studies Of

    Proc. Natl. Acad. Sci. USA Vol. 82, pp. 8483-8487, December 1985 Cell Biology Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets (antimitotic drug/microtubules/microtubule-associated proteins) MARK E. STEARNS*t, DONALD P. JENKINS*, AND KENNETH D. TEWt *Department of Anatomy, Georgetown University Schools of Medicine and Dentistry, Washington, DC 20007; and tDepartments of Medicine and Pharmacology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007 Communicated by Keith R. Porter, July 8, 1985 ABSTRACT Fluorescence-microscopic studies with of DnsEM was measured by their effect on the colony- dansylated estramustine (DnsEM) has permitted investigation forming ability of DU 145 human prostatic carcinoma cells. of the mechanism of estramustine (EM) uptake in live human The results presented here show that DnsEM is as cytotoxic prostatic tumor cells (DU 145). DnsEM appeared to enter cells to cells as EM and can be used as a direct probe for analysis rapidly at the peripheral cell margins. A progressive increase of EM's mechanism of action in live cells. in fluorescence was observed until the perinuclear material and cytoplasm were labeled brightly and the nucleoplasm was METHODS labeled faintly. Light microscopy showed that DnsEM is assimilated first in preexisting vesicles and then in numerous Dansylation of EM. The synthesis of DnsEM involved the newly created vesicles that accumulate in the cytoplasm and dansylation reaction as first introduced by Gray (9) and around the nucleus. Colony-forming assays showed EM and modified by Jenkins (10). Fifty milligrams of 5- DnsEM to be equally cytotoxic to cultured DU 145 cells.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Thermodynamic Quantities for the Ionization Reactions of Buffers

    Thermodynamic Quantities for the Ionization Reactions of Buffers

    Thermodynamic Quantities for the Ionization Reactions of Buffers Robert N. Goldberg,a… Nand Kishore,b… and Rebecca M. Lennen Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899 ͑Received 21 June 2001; accepted 16 September 2001; published 24 April 2002͒ This review contains selected values of thermodynamic quantities for the aqueous ionization reactions of 64 buffers, many of which are used in biological research. Since the aim is to be able to predict values of the ionization constant at temperatures not too far from ambient, the thermodynamic quantities which are tabulated are the pK, standard ⌬ ؠ ⌬ molar Gibbs energy rG , standard molar enthalpy rH°, and standard molar heat ca- ؠ ⌬ pacity change rC p for each of the ionization reactions at the temperature T ϭ298.15 K and the pressure pϭ0.1 MPa. The standard state is the hypothetical ideal solution of unit molality. The chemical name͑s͒ and CAS registry number, structure, empirical formula, and molecular weight are given for each buffer considered herein. The selection of the values of the thermodynamic quantities for each buffer is discussed. © 2002 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. Key words: buffers; enthalpy; equilibrium constant; evaluated data; Gibbs free energy; heat capacity; ionization; pK; thermodynamic properties. Contents 7.19. CAPSO.............................. 263 7.20. Carbonate............................ 264 7.21. CHES............................... 264 1. Introduction................................ 232 7.22. Citrate............................... 265 2. Thermodynamic Background.................. 233 7.23. L-Cysteine............................ 268 3. Presentation of Data......................... 234 7.24. Diethanolamine........................ 270 4. Evaluation of Data. ........................ 235 7.25. Diglycolate..........................
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
  • Fluoxymesterone-Dea Schedule Iii Androfluorene

    Fluoxymesterone-Dea Schedule Iii Androfluorene

    Cat. No. F7751 FLUOXYMESTERONE--DEA SCHEDULE III ANDROFLUORENE Androgen. OH Mol. Formula: C20H29FO3 HO H3C CH3 Mol. Wt.: 336.45 (anhyd.) F H3C m.p.: 288-290°C CAS Registry No.: 76-43-7 O Chemical Name: 4-Androsten-9a-fluoro-17a-methyl-11b,17b-diol-3-one 22 Physical Properties: White photosensitive solid. [a] D = +102.34° (c = 0.47, EtOH). Caution: Due care should be exercised to prevent skin contact, ingestion or inhalation of this compound. Storage: Store tightly sealed at room temperature, protected from exposure to light. Solubility: Soluble in ethanol (7.3 mg/ml) or water (< 0.5 mg/ml). Solubility in 45% aqueous (w/v) 2-hydroxypropyl-b- cyclodextrin (Cat. No. H-107): 6.4 mg/ml. Disposal: Dissolve or mix the compound with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. This product is controlled by the Drug Enforcement Administration. Appropriate security must be maintained until the substance is destroyed. Records must be kept which detail the ultimate disposition of the material. References: 1. Merck Index 11th Ed., No. 4113. 2. Saborido, A., Vila, J., Molano, F., Megias, A. “Effect of steroids on mitochondria and sarcotubular system of skeletal muscle.” J. Appl. Physiol. 70(3), 1038 (1991). 3. Fernandez, L., Chirino, R., Boada, L.D., Navarro, D., Cabrera, N., del Rio, I., Diaz-Chico, B.N. “Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes.” Endocrinology 134(3), 1401 (1994). CONTROLLED SUBSTANCE - DEA LICENSE REQUIRED (III) Rev.
  • Model Answer

    Model Answer

    MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ Important Instructions to examiners: 1) The answers should be examined by key words and not as word-to-word as given in the model answer scheme. 2) The model answer and the answer written by candidate may vary but the examiner may try to assess the understanding level of the candidate. 3) The language errors such as grammatical, spelling errors should not be given more Importance (Not applicable for subject English and Communication Skills. 4) While assessing figures, examiner may give credit for principal components indicated in the figure. The figures drawn by candidate and model answer may vary. The examiner may give credit for anyequivalent figure drawn. 5) Credits may be given step wise for numerical problems. In some cases, the assumed constant values may vary and there may be some difference in the candidate’s answers and model answer. 6) In case of some questions credit may be given by judgement on part of examiner of relevant answer based on candidate’s understanding. 7) For programming language papers, credit may be given to any other program based on equivalent concept. Page no.1/28 MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ 1 ANSWER ANY EIGHT OF THE FOLLOWING. 16M (8x2) 1 a) State any four ideal properties of buffer solution. ANY The pH of buffer solution remains constant.
  • Buffers a Guide for the Preparation and Use of Buffers in Biological Systems Calbiochem® Buffers a Guide for the Preparation and Use of Buffers in Biological Systems

    Buffers a Guide for the Preparation and Use of Buffers in Biological Systems Calbiochem® Buffers a Guide for the Preparation and Use of Buffers in Biological Systems

    Buffers A guide for the preparation and use of buffers in biological systems Calbiochem® Buffers A guide for the preparation and use of buffers in biological systems Chandra Mohan, Ph.D. EMD, San Diego, California © EMD, an affiliate of Merck KGaA, Darmstadt, Germany. All rights reserved. A word to our valued customers We are pleased to present to you the newest edition of Buffers: A Guide for the Preparation and Use of Buffers in Biological Systems. This practical resource has been especially revamped for use by researchers in the biological sciences. This publication is a part of our continuing commitment to provide useful product information and exceptional service to you, our customers. You will find this booklet a highly useful resource, whether you are just beginning your research work or training the newest researchers in your laboratory. Over the past several years, EMD Biosciences has clearly emerged as a world leader in providing highly innovative products for your research needs in Signal Transduction, including the areas of Cancer Biology, Alzheimer’s Disease, Diabetes, Hypertension, Inflammation, and Apoptosis. Please call us today for a free copy of our LATEST Catalog that includes tools for signal transduction and life science research. If you have used our products in the past, we thank you for your support and confidence in our products, and if you are just beginning your research career, please call us and give us the opportunity to demonstrate our exceptional customer and technical service. Corrine Fetherston Sr. Director, Marketing ii Table of Contents: Why does Calbiochem® Biochemicals Publish a Booklet on Buffers? .
  • Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic

    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic

    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic 18F-FDG Activity in the Intestine Jan D. Soyka1, Klaus Strobel1, Patrick Veit-Haibach1, Niklaus G. Schaefer1, Daniel T. Schmid1, Alois Tschopp2, and Thomas F. Hany1 1Department of Nuclear Medicine, University Hospital, Zurich, Switzerland; and 2Department for Biostatistics, University of Zurich, Zurich, Switzerland Our objective was to investigate the use of bowel preparation be- mendations have been made in order to reduce physiologic fore 18F-FDG PET/CT to reduce intestinal 18F-FDG uptake. uptake of 18F-FDG in the intestine or to improve the ability Methods: Sixty-five patients with abdominal neoplasias were to evaluate intestinal structures (5–8). However, no published assigned either to a bowel-preparation group (n 5 26) or to a na- tive group (n 5 39). 18F-FDG activity was measured in the small study has proven that bowel preparation before PET/CT intestine and the colon. Results: In the 26 patients with bowel is beneficial. We therefore conducted a naturally randomized preparation, average maximal standardized uptake value (SUV- and single-blinded study to evaluate the effects of bowel max) was 3.5 in the small intestine and 4.4 in the colon. In the cleansing on intestinal 18F-FDGactivityinPET/CT. 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. 18F-FDG activity im- MATERIALS AND METHODS paired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P 5 0.5). SUV- This prospective, naturally randomized, and single-blinded max in the colon was significantly higher in the bowel-prepara- study was approved by our local ethics committee.
  • Frequently Asked Questions for Addison Patients

    Frequently Asked Questions for Addison Patients

    FREQUENTLY ASKED QUESTIONS FOR ADDISON PATIENTS TABLE OF CONTENT (Place your cursor over the subject line, hold down the Control Button and Click your mouse. To get back to the Table of Content, hold down the Control Button and press the Home key) ADDISONIAN CRISIS / EMERGENCY ADDISONS AND OTHER DISORDERS ADDISONS AND OTHER MEDICATIONS ADRENALINE BLOOD PRESSURE COMMON COLD/FLU/OTHER ILLNESS CORTISOL DAY CURVE CORTISOL MEDICATION CRAMPS DIABETES DIAGNOSING ADDISONS EXERCISE / SPORTS FATIGUE FLORINEF / SALT / SODIUM HERBAL / VITAMIN SUPPLEMENTS HYPERPIGMENTATION IMMUNIZATION MENOPAUSE, PREGNANCY, HORMONE REPLACEMENT, BIRTH CONTROL, HYSTERECTOMY MISCELLANEOUS OSTEOPOROSIS SECONDARY ADDISON’S SHIFT WORK SLEEP 1 STRESS DOSING SURGICAL, MEDICAL, DENTAL PROCEDURES THYROID TRAVEL WEIGHT GAIN 2 ADDISONIAN CRISIS / EMERGENCY How do you know when to call an ambulance? If you are careful, you should not have to call an ambulance. If someone with adrenal insufficiency has gastrointestinal problems and is unable to keep down their cortisol or other glucocorticoid for more than 24 hrs, they should be taken to an emergency department so they can be given intravenous solucortef and saline. It is not appropriate to wait until they are so ill that they cannot be taken to the hospital by a family member. If the individual is unable to retain anything by mouth and is very ill, or if they have had a sudden stress such as a fall or an infection, then it would be necessary for them to go by ambulance as soon as possible. It is important that you should have an emergency kit at home and that someone in the household knows how to use it.
  • Statistical Analysis Plan: IT001-302

    Statistical Analysis Plan: IT001-302

    Statistical Analysis Plan: IT001-302 Study Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probenecid versus intravenous ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate for treatment of complicated urinary tract infections in adults. Study Number: IT001-302 Study Phase: Phase 3 Product Name: Sulopenem (CP-70,429), Sulopenem-etzadroxil (PF-03709270)/Probenecid Indication: Complicated urinary tract infection Study Statistician: Michael Zelasky Study Clinician: Steven I. Aronin, M.D. Sponsor: Iterum Therapeutics International Limited 20 Research Parkway, Suite A Old Saybrook, CT 06475 Final SAP Date: September 25, 2019 Revised SAP Date: February 11, 2020 Protocol Version: January 16, 2020 Confidentiality Statement This document is strictly confidential. It was developed by Iterum Therapeutics US Limited should not be disclosed to a third party, with the exception of regulatory agencies and study audit personnel. Reproduction, modification or adaptation, in part or in total, is strictly forbidden without prior written approval by Iterum Therapeutics US Limited Digitally signed by Anita F Das DN: cn=Anita F Das, o, ou, [email protected]. Anita F Das com, c=US Date: 2020.02.12 12:57:12 -08'00' Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 TABLE OF CONTENTS TABLE OF CONTENTS...........................................................................................................